| 1 |
34333803 | Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects. | 2021 Dec |
2 |
| 2 |
31990936 | Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial. | 2020 |
2 |
| 3 |
32663193 | Hematopoietic cell- versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice. | 2020 Aug 20 |
4 |
| 4 |
30738832 | Oxidized LDL upregulates macrophage DPP4 expression via TLR4/TRIF/CD36 pathways. | 2019 Mar |
1 |
| 5 |
29573110 | SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis. | 2018 Aug |
1 |
| 6 |
28213130 | Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes. | 2017 Apr 1 |
1 |
| 7 |
28626771 | Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus. | 2017 |
4 |
| 8 |
27249660 | Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. | 2016 Jun |
1 |
| 9 |
25637323 | Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus. | 2015 Feb 15 |
4 |
| 10 |
25664602 | Effect of vildagliptin on hepatic steatosis. | 2015 Apr |
1 |
| 11 |
26072069 | Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease. | 2015 Jun |
2 |
| 12 |
26259132 | Plasma DPP4 Activities Are Associated With Osteoporosis in Postmenopausal Women With Normal Glucose Tolerance. | 2015 Oct |
2 |
| 13 |
26318108 | Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of subclinical atherosclerosis in Chinese patients with newly diagnosed type 2 diabetes: a cross-sectional study. | 2015 Oct |
1 |
| 14 |
26616595 | Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin. | 2015 Dec |
1 |
| 15 |
25231186 | Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males. | 2014 Nov 1 |
2 |
| 16 |
23994650 | The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. | 2013 Nov |
2 |
| 17 |
24362783 | [Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors]. | 2013 Dec |
2 |
| 18 |
22923161 | Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. | 2012 Sep |
1 |